1. Analyst View
2. Research Methodology
3. The Global Burden of Cancer
3.1 Cancer - A Leading Cause of Death
3.2 Current and Future Cancer Cases: By Type and Geography
3.3 Common Causes of Cancer
4. Global Cancer Market Outlook to 2015
4.1 Current and Future Growth
4.2 Analysis by Therapeutic Areas
5. Monoclonal Antibodies: Introduction and Working
5.1 Types of Mabs
5.1.1 Murine Antibodies
5.1.2 Chimeric and Humanized Antibodies
5.1.3 Fully Human Antibodies
5.2 Conjugated Cancer Therapies using MAbs
5.2.1 Radioimmunotherapy
5.2.2 Antibody-directed Enzyme Pro-drug Therapy (ADEPT)
5.2.3 Immunoliposomes
5.2.4 Immunotoxin
5.2.5 Immunocytokine
5.3 mAb Therapies
5.3.1 Avastin/Bevacizumab
5.3.2 Rituxan/Rituximab
5.3.3 Herceptin/Trastuzumab
5.3.4 Erbitux/Cetuximab
5.3.5 Vectibix/Panitumumab
5.3.6 Campath/Alemtuzumab
5.3.7 Zevalin/ Ibritumomab
5.3.8 Bexxar/Tositumomab
5.3.9 Arzerra/Ofatumumab
6. Industry Trends and Drivers
6.1 Strategic Activity Building Up in the Market
6.2 New Approvals Showing Promising Future
6.3 Bispecific Antibodies: Emerging Therapeutic Treatment
6.4 Japan Gearing-up for Cancer Antibodies
7. Global Anti-Neoplastic mAbs Market Outlook to 2015
7.1 Market Size
7.2 Anti-Neoplastic mAbs: Approval History and Market Share
7.3 Anti-Neoplastic mAbs: Current and Future Market Size
7.3.1 Avastin (Bevacizumab)
7.3.2 MabThera/Rituxan (Rituximab)
7.3.3 Herceptin (Trastuzumab)
7.3.4 Erbitux (Cetuximab)
7.3.5 Vectibix (Panitumumab)
7.4 Country-Level Analysis
7.4.1 US
7.4.2 Japan
7.4.3 Europe
7.5 Market Share of Key Players
8. Pipeline Analysis for Anti-Neoplastic Monoclonal Antibodies
9. Competitive Landscape
9.1 Roche
9.2 Immunomedics
9.3 Bristol-Myers Squibb
9.4 AstraZeneca
9.5 Eli Lilly
9.6 Amgen